What kind of kidney injury does Interferon-α cause?

Glomerular Injury / Proteinuria — Damage to the filtration barrier — podocyte injury, FSGS and protein leak from VEGF and mTOR blockade. Other reported patterns: Thrombotic Microangiopathy.

Is kidney injury from Interferon-α reversible?

Variable. Typical onset: Subacute — weeks to months of therapy..

How should kidney function be monitored during Interferon-α therapy?

Baseline and serial urine protein quantification (UPCR or spot ratio) every 4-8 weeks during therapy; new or rising proteinuria is the earliest signal of IFN glomerulopathy.; Monitor blood pressure and check for new edema, which often accompany the emerging nephrotic syndrome.; Screen for TMA when there is thrombocytopenia, falling hemoglobin, schistocytes on smear, elevated LDH, and low haptoglobin alongside renal dysfunction.; Refer for kidney biopsy when nephrotic-range proteinuria or unexplained AKI develops, and hold the drug pending evaluation.; Serum creatinine/eGFR during therapy to detect declining renal function.

How can kidney injury from Interferon-α be prevented?

Dose-reduce or avoid the pegylated interferon-α formulations at CrCl <50 mL/min, per label — they accumulate in renal impairment

Who is at higher risk of kidney injury from Interferon-α?

Black race / APOL1 high-risk genotype.

Back to explorer

Printable monograph

Cytokine

Interferon-α

Intron A · Roferon-A · IFN

Cytokine · approved 1986 · 8 citations

Up to date· through 2025

Deeply sourced7/9 · 6 signals

Met: 8 citations
Not met: 12+ references
Met: Accrued over 10+ years (span: 28y)
Met: Beyond single case reports
Met: High-impact journal
Met: Landmark reference
Met: Current through 2025
Not met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

A podocyte poison — the classic trigger of collapsing FSGS in APOL1 carriers.

SevereCytokine immunotherapy

MelanomaRenal cellCMLKaposi sarcoma

§01

Signature kidney injury

Signature lesion

Glomerular Injury / Proteinuria

Rare; best characterized by an 11-case biopsy series, disproportionately in Black patients (APOL1).Source: Markowitz et al., CJASN 2010

Onset & rechallenge

Time to injurySubacute (~1–6 weeks)

Develops over weeks to months of therapy.

Distilled from: “Subacute — weeks to months of therapy.”

Long-term outlook & thresholds

Early-detection biomarkers

Quantitative proteinuria (24-h urine protein or protein–creatinine ratio) — Podocyte injury — collapsing FSGS, the signature glomerular lesion. In the defining biopsy series of 11 collapsing-FSGS cases on interferon, patients presented with nephrotic-range proteinuria (mean 9.7 g/24 h across all 11), and in the seven of those eleven with follow-up proteinuria data the mean fell from 9.9 to 3.0 g/d after stopping the drug — the higher baseline is that subset's own mean, not a second figure for the whole series — so it is both the presenting signal and the metric that tracks recovery. Two limits must travel with it: proteinuria appeared alongside an already-elevated creatinine (mean 3.5 mg/dl), not before it, so this is not a lead-time marker; and only one of the eleven patients was an oncology patient receiving interferon-alfa, the rest being hepatitis C, multiple sclerosis and pulmonary fibrosis across all three interferon isoforms.PMID 20203164 (opens PubMed in a new tab)
Platelet count with microangiopathic haemolysis markers — Interferon-associated thrombotic microangiopathy / HUS. In two chronic-myeloid-leukaemia patients treated with interferon-alfa, HUS was recognised by progressive renal dysfunction, thrombocytopenia, microangiopathic haemolytic anaemia and biopsy-proven renal TMA. The instructive detail is what the markers do and do not predict: withdrawing the drug promptly resolved the thrombocytopenia and haemolysis in both, while renal failure did not follow suit and progressed to dialysis dependence in one — so the haematologic panel is an attribution and stop-the-drug signal, not a guarantee of renal recovery. Case-report level (n = 2), and both patients also received hydroxycarbamide.PMID 12613003 (opens PubMed in a new tab)

Long-term outcome and threshold data distilled from the agent's cited literature — educational, not a substitute for the primary sources.

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

Glomerular Injury / Proteinuria#1 · Signaturequalitative — no citable incidence
Damage to the filtration barrier — podocyte injury, FSGS and protein leak from VEGF and mTOR blockade.
Thrombotic MicroangiopathySecondaryqualitative — no citable incidence
Endothelial injury with microvascular thrombi, hemolysis and thrombocytopenia — gemcitabine, mitomycin C, anti-VEGF.

§03

Kidney injury

Mechanism of kidney injury

Direct interferon-induced podocyte injury (a podocytopathy), with endothelial tubuloreticular inclusions on electron microscopy — strongly associated with APOL1 high-risk genotype.

Clinical presentation

Nephrotic-range proteinuria (mean ~9.7 g/day), AKI (mean creatinine ~3.5 mg/dL) and edema.

Management

Discontinue interferon (the primary treatment); supportive nephrotic care. Immunosuppression is generally ineffective.Lesion-level management framework

Risk factors

Black race / APOL1 high-risk genotype

Prevention

Dose-reduce or avoid the pegylated interferon-α formulations at CrCl <50 mL/min, per label — they accumulate in renal impairment

Anticancer mechanism· how it treats cancer

Immunomodulatory, antiproliferative cytokine. Historically melanoma, renal cell, CML and Kaposi sarcoma.

Note · Largely historical, but a key teaching case for collapsing FSGS and APOL1.

§04

Clinical depth

Renal dose adjustment

No renal dose threshold is established for the glomerular injury itself, which is an immune-mediated, idiosyncratic reaction rather than a dose-dependent toxicity. However, pegylated interferon-α formulations accumulate in renal impairment and each carries its own banding: peginterferon alfa-2b (Sylatron) is reduced 25% at CrCl 30-50 and 50% at CrCl <30 or ESRD on dialysis, while peginterferon alfa-2a (Pegasys) keeps the full 180 mcg weekly at CrCl 30-50 and drops to 135 mcg only below 30 including hemodialysis, with caution advised at CrCl ≤50. Neither label directs avoidance. Discontinuation, not dose reduction, is the management when nephrotic-range proteinuria, rising creatinine, or TMA emerges.

Dialyzability & ESKD dosing

Limited data; standard interferon-α is a ~19 kDa protein cleared largely by renal catabolism and tubular reabsorption, and is not meaningfully removed by conventional hemodialysis. Pegylation further reduces clearance and dialyzability, so accumulation in dialysis-dependent patients is expected and supports reduced/avoided dosing rather than reliance on dialytic removal.

Differential diagnosis

Distinguish IFN-induced collapsing FSGS (heavy proteinuria, often with tubuloreticular inclusions/'interferon footprints' on EM) from HIV-associated nephropathy, pamidronate-related collapsing GN, and primary FSGS. IFN-associated TMA must be separated from other drug-induced TMA, malignant hypertension, and primary TTP/aHUS by exposure timing (often after months-years of therapy) and improvement on drug withdrawal, whereas underlying HCV cryoglobulinemia points to MPGN rather than a direct IFN effect.

Monitoring

Baseline and serial urine protein quantification (UPCR or spot ratio) every 4-8 weeks during therapy; new or rising proteinuria is the earliest signal of IFN glomerulopathy.
Monitor blood pressure and check for new edema, which often accompany the emerging nephrotic syndrome.
Screen for TMA when there is thrombocytopenia, falling hemoglobin, schistocytes on smear, elevated LDH, and low haptoglobin alongside renal dysfunction.
Refer for kidney biopsy when nephrotic-range proteinuria or unexplained AKI develops, and hold the drug pending evaluation.
Serum creatinine/eGFR during therapy to detect declining renal function

Key trials & series

Markowitz et al. (J Am Soc Nephrol 2010) - landmark renal-biopsy series linking all three interferon types (especially IFN-β) to collapsing and non-collapsing FSGS with nephrotic-range proteinuria.
Nichols et al. / pharmacovigilance and pooled case-series reviews of interferon-associated thrombotic microangiopathy, characterizing IFN-β > IFN-α TMA presenting with AKI, hypertension, and hemolysis often after prolonged exposure.
Multiple published case series of pegylated IFN-α (± ribavirin) for hepatitis C reporting biopsy-proven FSGS, minimal change disease, and membranoproliferative/cryoglobulinemic GN.

Clinical pearls

All three interferons can cause glomerular disease, but the classic IFN lesion is collapsing FSGS presenting with abrupt heavy proteinuria and rapidly declining GFR.
Tubuloreticular inclusions ('interferon footprints') in glomerular endothelium on electron microscopy are a histologic clue to an interferon-driven process.
Withdrawal of the drug is the primary treatment and often the main hope for renal recovery; steroid response is inconsistent and collapsing FSGS frequently progresses to ESKD despite stopping.
Interferon-associated TMA is a distinct, often delayed and severe presentation (AKI, malignant-range hypertension, microangiopathic hemolysis) that does not respond to plasma exchange and hinges on prompt discontinuation.

Where it strikes· nephron segments & injury signatures

Nephron segments

Glomerulus

Filtration barrier (podocytes + endothelium)

Injury signatures

Glomerular Injury / Proteinuria Thrombotic Microangiopathy

Beyond the kidney — non-renal toxicities· 2 organ systems

Class-level context for the major non-renal toxicities of the Cytokine class.

Immune / Infusion

CRS, infusion reactions, irAEs, anaphylaxis

Flu-like syndrome, capillary leak (IL-2)

Neurologic

Neuropathy, encephalopathy, ICANS, PRES

Depression, fatigue (interferon)

§05

References

5 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.

Evidence accrual

5 references · 2010–2025 · 2 since 2023

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

Case reports — ranked by strength· 3

Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.

CaseB · ModerateThrombotic microangiopathy associated with alpha-interferon therapy for chronic myelocytic leukemia.Honda K et al. · Am J Kidney Dis 1997 · PMID 9214412A CML patient on long-term IFN-alpha developed renal insufficiency with nephrotic-range proteinuria and biopsy-proven renal thrombotic microangiopathy resembling hemolytic-uremic syndrome.CaseB · ModerateInterferon Induced Focal Segmental Glomerulosclerosis.Kayar Y et al. · Case Rep Nephrol 2016 · PMID 27847659A Behcet's disease patient treated with IFN-alpha for uveitis presented with acute renal failure and nephrotic syndrome, with kidney biopsy confirming focal segmental glomerulosclerosis attributed to interferon.CaseB · ModerateInterferon-alpha-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy.Shah M et al. · Cancer 1998 · PMID 9806652Two CML patients on IFN-alpha after high-dose chemotherapy developed acute renal failure with massive proteinuria; biopsies showed focal segmental glomerulosclerosis.

Guidelines & consensus· 13

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Interferon-α sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.

Phenotype-similar agents· the numbered markers on the map above

Pamidronate

Aredia · Bisphosphonate

Profile

Collapsing FSGS — first drug ever linked.

GLOM

Severe#1 · 65% phenotype match

Fruquintinib

Fruzaqla · VEGFR TKI

Profile

2023 colorectal VEGFR-TKI; hypertension and proteinuria, class effect.

HTNGLOMTMA

Moderate#2 · 64% phenotype match

Mitomycin C

Mutamycin · Antitumor antibiotic

Profile

Prototype dose-dependent TMA.

TMAGLOMCYST

Severe#3 · 62% phenotype match

Bortezomib

Velcade · Proteasome inhibitor

Profile

Rare TMA; reverses myeloma cast nephropathy.

TMAGLOM

Moderate#4 · 61% phenotype match

Dasatinib

Sprycel · BCR-ABL TKI

Profile

Nephrotic-range proteinuria — a notable signal.

GLOM

Moderate#5 · 60% phenotype match

Ziv-aflibercept

Zaltrap · VEGF trap

Profile

Hypertension and proteinuria like bevacizumab.

HTNGLOMTMA

Moderate#6 · 56% phenotype match

Compare Interferon-α with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across Cytokines & enzymes

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile.

1AsparaginasePRE — Prerenal / Hemodynamic AKIMild
2PegaspargasePRE — Prerenal / Hemodynamic AKIFAERS AKIMild
3TasonerminPRE — Prerenal / Hemodynamic AKIModerate
4Interleukin-2 (high-dose)PRE — Prerenal / Hemodynamic AKIFAERS AKIModerate
5Interferon-α· this agentGLOM — Glomerular Injury / ProteinuriaSevere

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.

Who studies this

The leading contributors to Interferon-α’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Interferon-α; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.

Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 127 clinical records among the 300 most-relevant of 339 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.